Author

B. E. Hall

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. Byford· 1 shared A. Kulkarni· 1 shared A. Loboda· 1 shared A. Palmieri· 1 shared A. R. Ott· 1 shared B. Joyce-Shaikh· 1 shared C. Chappell· 1 shared C. Mieczkowski· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Byford

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Multiprotein Assemblies, Phosphorylation and Dephosphorylation in Neuronal Cytoskeleton

N. A. Kurochkina, M. R. Sapio, M. J. Iadarola, B. E. Hall, A. Kulkarni

This study examines how mutations in BARD1 ankyrin repeats correlate with phosphorylation sites and conformational changes, suggesting implications for Alzheimer's disease pathogenesis.

bioRxiv · Jun 21, 2023 · PreprintBiochemistry

SEC-seq: Association of molecular signatures with antibody secretion in thousands of single human plasma cells

R. Y.-H. Cheng, J. de Rutte, A. R. Ott, L. Bosler, W.-Y. Kuo, J. Liang, B. E. Hall, D. J. Rawlings, D. Di Carlo, R. G. James

The paper introduces SEC-seq, a method to link antibody secretion with surface markers and transcriptomes in single human plasma cells, revealing pathways associated with high IgG secretion.

bioRxiv · Aug 25, 2022Bioengineering

Antibodies to ILT3 abrogate myeloid immunosuppression and enable tumor killing

P. E. Brandish, A. Palmieri, G. Ayanoglu, J. Baker, R. Bueno, A. Byford, M. Caniga, C. Chappell, H. Cherwinski, D. J. Cua, X. Du, L. Fayadat-Dilman, B. E. Hall, H. Issafras, B. Joyce-Shaikh, , J. Zhang-Hoover

This study shows anti-ILT3 antibodies block myeloid immunosuppression and enhance tumor killing in solid tumors.

bioRxiv · Dec 18, 2021 · PreprintCancer Biology